NCT00746382View on ClinicalTrials.gov

A Placebo Controlled 4 Week Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild Atopic Dermatitis (RO-2351-001-EM)

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 30, 2008

Primary Completion Date

June 30, 2009

Study Completion Date

September 30, 2009

Conditions
Dermatitis
Interventions
DRUG

Roflumilast cream

Roflumilast cream 0.5% versus Placebo cream

DRUG

Placebo cream

Placebo cream

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
collaborator

Fougera Pharmaceuticals Inc.

INDUSTRY

lead

AstraZeneca

INDUSTRY